ArticleEuropean journal of nutrition2026
Stigmasterol upregulates Akt/mTOR/p70S6K signaling through SYVN1 to alleviate osteoporosis in ovariectomized rats.
Article in European journal of nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundTo investigate the effects and mechanism of action of the main component, Stigmasterol (STG), of Liuwei Dihuang Pill (LP) on postmenopausal osteoporosis (PMOP) in ovariectomized (OVX) rats.
methodsCell viability was assessed using the cell counting kit 8 (CCK-8) assay. Osteoblast differentiation was evaluated through alkaline phosphatase (ALP) activity assay, ALP staining, and Alizarin Red S staining. Expression levels were assessed by real-time quantitative PCR (RT-qPCR), Western blot, and immunohistochemistry. Immunofluorescence was used to observe protein colocalization. Protein–protein interactions were detected using co-immunoprecipitation (Co-IP) and Molecular docking and drug affinity responsive target stability (DARTS) assays. Additionally, an OVX rat model was established through ovariectomy surgery. Utilizing micro-computed tomography (CT), we scanned and analyzed the fine structure of the rat femoral trabeculae across various groups, thereby gathering pertinent data. Enzyme-linked immunosorbent assay (ELISA) was performed to determine the levels of E2, key bone immune regulatory markers, bone turnover markers, and pro-inflammatory factor in serum.
resultsThe main components of LP, including Quercetin, Kaempferol, β-sitosterol, and STG, significantly promote osteogenic differentiation of osteoblasts, with STG having the most significant effect. Moreover, STG also notably enhances the upregulation of the Akt/mTOR/ p70S6 kinase (p70S6K) signaling pathway. Bioinformatics analysis predicted the potential ubiquitin ligase synoviolin 1 (SYVN1) for Akt, which was experimentally validated. Molecular docking between STG and SYVN1 verified their binding activity, and STG downregulated the expression of SYVN1. Overexpression of SYVN1 reversed the promoting effect of STG on osteoblast differentiation and activation of the Akt/mTOR/p70S6K pathway. Furthermore, STG upregulated uterine index and serum levels of E2, OPG, BALP, PINP, OCN, and CTX-1, and downregulated levels of RANKL, IL-6, and TNF-α in OVX rats. Meanwhile, STG promoted the expression of OCN and inhibited the expression of NFATc1 and cathepsin-K in the femurs of OVX rats. Additionally, STG activated the Akt/mTOR/p70S6K pathway in the femurs of OVX rats. However, overexpressing SYVN1 reversed the effects of STG on OVX rats.
conclusionSTG upregulated the Akt/mTOR/p70S6K signaling via SYVN1 to alleviate osteoporosis in OVX rats. Therefore, this study will provide new insights into discovering novel approaches for treating PMOP.
Indexed as
Identifiers
41886086What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.